tiprankstipranks
Advertisement
Advertisement

AZN Stock Latest News

BUY Rating on AstraZeneca Driven by Camizestrant’s Phase III SERENA-6 PFS2 Catalyst and Key FDA ODAC Milestone in HR+ Breast Cancer
RatingsBUY Rating on AstraZeneca Driven by Camizestrant’s Phase III SERENA-6 PFS2 Catalyst and Key FDA ODAC Milestone in HR+ Breast Cancer
2h ago
AZN
AstraZeneca Board Member Rene Haas to Step Down After New CEO Appointment
PremiumCompany Announcements
AstraZeneca Board Member Rene Haas to Step Down After New CEO Appointment
4h ago
AZN
Osimertinib Cements Lead in EGFR Lung Cancer as AstraZeneca Updates Key Phase 3 Trial
PremiumCompany Announcements
Osimertinib Cements Lead in EGFR Lung Cancer as AstraZeneca Updates Key Phase 3 Trial
2d ago
AZN
AstraZeneca’s Baxdrostat Trial Completion Puts Resistant Hypertension Opportunity in Focus
PremiumCompany Announcements
AstraZeneca’s Baxdrostat Trial Completion Puts Resistant Hypertension Opportunity in Focus
2d ago
AZN
AstraZeneca announces I CAN Phase III trial of Ultomiris met primary endpoint
PremiumThe Fly
AstraZeneca announces I CAN Phase III trial of Ultomiris met primary endpoint
2d ago
AZN
AstraZeneca’s Ultomiris Hits Phase III Mark in Rare Kidney Disease
PremiumCompany AnnouncementsAstraZeneca’s Ultomiris Hits Phase III Mark in Rare Kidney Disease
2d ago
AZN
AstraZeneca says tozorakimab met primary endpoint in Phase III MIRANDA trial
Premium
The Fly
AstraZeneca says tozorakimab met primary endpoint in Phase III MIRANDA trial
3d ago
AZN
AstraZeneca announces tozorakimab met primary endpoint in Phase III trial
Premium
The Fly
AstraZeneca announces tozorakimab met primary endpoint in Phase III trial
3d ago
AZN
AstraZeneca’s Tozorakimab Delivers Third Positive Phase III Result in COPD
PremiumCompany Announcements
AstraZeneca’s Tozorakimab Delivers Third Positive Phase III Result in COPD
3d ago
AZN
Trump names Erica Schwartz CDC Director
PremiumThe Fly
Trump names Erica Schwartz CDC Director
7d ago
AZN
BMY
AstraZeneca Nears Key COPD Milestone With Phase III Tozorakimab Trial
PremiumCompany Announcements
AstraZeneca Nears Key COPD Milestone With Phase III Tozorakimab Trial
7d ago
AZN
AstraZeneca’s OBERON COPD Trial Reaches Completion, Setting Up a Key Catalyst for AZN
PremiumCompany Announcements
AstraZeneca’s OBERON COPD Trial Reaches Completion, Setting Up a Key Catalyst for AZN
7d ago
AZN
Trump Trade: White House launches space nuclear initiative
PremiumThe FlyTrump Trade: White House launches space nuclear initiative
7d ago
F
GM
Drugmakers raised prices on hundreds of drugs, NBC News reports
Premium
The Fly
Drugmakers raised prices on hundreds of drugs, NBC News reports
7d ago
AZN
BMY
CDT Equity expands multi-pathway value creation strategy across pharma, IP
Premium
The Fly
CDT Equity expands multi-pathway value creation strategy across pharma, IP
7d ago
AZN
CDT
AstraZeneca Completes Early Imaging Study in Crohn’s Disease, Nudging Pipeline Hopes for AZN
PremiumCompany Announcements
AstraZeneca Completes Early Imaging Study in Crohn’s Disease, Nudging Pipeline Hopes for AZN
9d ago
AZN
AstraZeneca: Expanding COPD Biologic Opportunity With Tozorakimab Underpins Buy Rating and Long‑Term Growth Upside
PremiumRatings
AstraZeneca: Expanding COPD Biologic Opportunity With Tozorakimab Underpins Buy Rating and Long‑Term Growth Upside
10d ago
AZN
AstraZeneca price target raised to 18,000 GBp from 17,000 GBp at Citi
PremiumThe Fly
AstraZeneca price target raised to 18,000 GBp from 17,000 GBp at Citi
13d ago
AZN
AstraZeneca Wins Strong Shareholder Backing at 2026 AGM
PremiumCompany Announcements
AstraZeneca Wins Strong Shareholder Backing at 2026 AGM
14d ago
AZN
ESPERANZA Update: Real-World Data Study Could Broaden AstraZeneca’s T-DXd Cancer Opportunity
PremiumCompany AnnouncementsESPERANZA Update: Real-World Data Study Could Broaden AstraZeneca’s T-DXd Cancer Opportunity
15d ago
AZN
AstraZeneca price target raised to 16,500 GBp from 16,000 GBp at Morgan Stanley
Premium
The Fly
AstraZeneca price target raised to 16,500 GBp from 16,000 GBp at Morgan Stanley
15d ago
AZN
AstraZeneca: Oncology and CVRM Momentum, Pipeline Progress, and FX Tailwinds Underpin Raised £165 Price Target and Buy Rating
Premium
Ratings
AstraZeneca: Oncology and CVRM Momentum, Pipeline Progress, and FX Tailwinds Underpin Raised £165 Price Target and Buy Rating
16d ago
AZN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >